Eleven Therapeutics

Company Overview

Snapshot

Founded in April 2020 by Prof. Yaniv Erlich, Prof. Greg Hannon, and Shaul Ilan, Eleven Therapeutics operates with 11–50 employees. The company has raised $25.9M across three funding rounds from three investors. In January 2024, Eleven Therapeutics appointed Dr. Paloma H Giangrande as Chief Technology Officer, signaling a strategic strengthening of its leadership in RNA therapeutics.

Business overview

Eleven Therapeutics is a startup focused on advancing mRNA therapeutics through its xRNA modality-based pipeline. The company aims to develop extended-release mRNA therapeutics (xRNA) to address unmet medical needs in metabolic, hematologic, and infectious disease areas. Its proprietary TERÅ platform facilitates high-throughput screening of xRNA molecules to identify non-canonical elements with superior stability and safety for chronic therapeutic applications, including fibrotic disorders. The company operates within the Health Tech & Life Sciences sector, specifically targeting Pharmaceuticals and Biotechnology markets.

Strategic signal

In January 2024, Eleven Therapeutics announced a research and development agreement with Dong-A ST for RNA-based gene therapy. This partnership indicates a strategic expansion of Eleven Therapeutics' therapeutic applications and validates its xRNA platform's potential for broader industry collaboration, suggesting a strong forward trajectory in gene therapy development.

Company Intelligence Q&A

What is Eleven Therapeutics' core focus?

Eleven Therapeutics is focused on the next generation of RNA therapeutics, specifically developing extended-release mRNA therapeutics (xRNA) for metabolic, hematologic, and infectious diseases.

When was Eleven Therapeutics founded and by whom?

Eleven Therapeutics was founded in April 2020 by Prof. Yaniv Erlich, Prof. Greg Hannon, and Shaul Ilan.

What significant leadership appointment did Eleven Therapeutics make recently?

In January 2024, Eleven Therapeutics welcomed Dr. Paloma H Giangrande as Chief Technology Officer, enhancing its leadership in the field of RNA therapeutics.

Has Eleven Therapeutics formed any notable partnerships?

In January 2024, Eleven Therapeutics signed an R&D agreement with Dong-A ST for RNA-based gene therapy. Additionally, in July 2023, Eleven Therapeutics partnered with Novo Nordisk to develop nucleic acid therapeutics.

When did Eleven Therapeutics raise seed funding?

Eleven Therapeutics raised seed funding in August 2022. The company also secured pre-seed funding in September 2020 from Entrée Capital.